title: Quality of life of patients and medical cost of "half elemental diet" as maintenance therapy for Crohn's disease: secondary outcomes of a randomised controlled trial.
abstract: OBJECTIVE
  Quality of life (QOL) of the patients and medical costs are important in current medical treatments, especially those for chronic diseases. We have reported the effectiveness of 'half elemental diet (ED)' as maintenance therapy for patients with Crohn's disease (CD). The aim of this study was to evaluate the QOL of CD patients and medical costs of half-ED.
  
  
  METHODS
  Fifty-one CD patients in remission were randomly assigned to a half-ED group (n=26) or a free diet group (n=25). The primary outcome measure was the occurrence of relapse during a 2-year period. This time, we investigated the QOL of the patients and medical costs of half-ED, as secondary outcomes. QOL was evaluated using the Japanese version of the IBDQ scoring system, and medical costs were calculated monthly from the receipts.
  
  
  RESULTS
  IBDQ score was not significantly different between the two groups at 1 and 13 months after the start of maintenance treatment. Medical costs were not significantly different between them either. This study showed that half-ED therapy did not affect the treatment of CD patients, neither regarding their QOL nor medical costs.
  
  
  CONCLUSIONS
  This study has confirmed this half-ED therapy is beneficial for patients with Crohn's disease.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Tohoku University Graduate School of Medicine, Aoba, Sendai, Japan. stakagi@mail.tains.tohoku.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Takagi
authors.forename: K
authors.initials: K
authors.lastname: Utsunomiya
authors.forename: S
authors.initials: S
authors.lastname: Kuriyama
authors.forename: H
authors.initials: H
authors.lastname: Yokoyama
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Umemura
authors.forename: M
authors.initials: M
authors.lastname: Iwabuchi
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Kinouchi
authors.forename: N
authors.initials: N
authors.lastname: Hiwatashi
authors.forename: Y
authors.initials: Y
authors.lastname: Funayama
authors.forename: I
authors.initials: I
authors.lastname: Sasaki
authors.forename: I
authors.initials: I
authors.lastname: Tsuji
authors.forename: T
authors.initials: T
authors.lastname: Shimosegawa
mesh_terms: D000328:Adult; D003365:Costs and Cost Analysis; D003424:Crohn Disease / Q000178:diet therapy* / Q000191:economics* / Q000517:prevention & control; D005260:Female; D005526:Food, Formulated / Q000191:economics*; D006801:Humans; D008297:Male; D011788:Quality of Life; D055502:Secondary Prevention; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult